The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta caused its own stock to drop during the gene therapy maker’s safety troubles ...

Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS ...

The FDA is adding a Boxed Warning label to delandistrogene moxeparvovec-rokl, a gene therapy for Duchenne muscular dystrophy, after reports of fatal liver injuries.

CAR T-cell therapies have revolutionized blood cancer treatment. Now, researchers with our Human Health Therapeutics Research ...

Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...

New York is known to be a high-tax and higher spending state. So, it’s curious that it is attempting to violate federal law ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress ...

Alzheimer's disease (AD) is a devastating cause of memory loss and cognitive decline, for which no curative treatment is ...

More than 74,000 participants in clinical trials lost their access to care as a result of Trump administration cuts, ...

To manage the finances of CAR-T therapies, which can cost up to $1 million each, health systems are increasingly using “pay for performance” deals, according to a Nov. 17 article in Specialty Pharmacy ...

Researchers said a survey of U.S. adults found 72% say sleepiness sometimes, often or always gets in the way of their ...

Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne ...